Device Label Translation: Reconciling Units, Symbols, and Released Versions

The Release Question: Fluent Is Not Reconciled

When medical device regulatory affairs (RA) and quality assurance (QA) teams evaluate translated labeling, packaging artwork, and instructions for use (IFU), the central verification question is straightforward but frequently mishandled: When we translate a device label and IFU, how do we check that units, symbols, and the released versions still match the approved master before artwork is issued?

The foundational operational rule is clear: Do not treat device label translation as finished when the translated words read fluently. In commercial medical device distribution, translation agencies and linguistic quality assurance (LQA) workflows focus primarily on natural syntax, localized vocabulary, and typographical layout. However, regulatory authorities and notified bodies do not audit labels for literary elegance. They audit labels for absolute technical fidelity, statutory prominence, standardized symbol recognition, and rigorous document version control against the approved design history file (DHF) and medical device file (MDF).

A device label or IFU language pack must only be released for printing, digital publication, or commercial packaging after successfully clearing three distinct, sequential reconciliation gates against the centrally approved master specification:

• Gate 1 (Units, Numbers, and Dates): SI unit symbols and numeric magnitudes remain locked unless an explicit, approved conversion (such as an authorized supplementary unit) is codified in the labeling specification. User-facing dates on US distribution packs strictly preserve four-digit year, two-digit month, and two-digit day (YYYY-MM-DD) syntax, and decimal markers or thousand separators are never inadvertently flipped by automated desktop publishing software.

• Gate 2 (Symbols, Glossaries, and Standard Editions): Every graphical symbol matches the standardized geometry, reference number, and edition cited in active regulatory lists—such as Commission Implementing Decision (EU) 2026/1231 for the European Union or FDA Recognized Consensus Standard Rec# 5-148 for the United States. Furthermore, symbols glossaries retain mandatory statutory fields without local paraphrase, and ISO 15223-1 Clause 5.7.8 (Translation) is used when an entity other than the manufacturer translates, not on manufacturer-controlled language packs.

• Gate 3 (Released Version Identity): Every translated artifact—from carton labels and primary pouch barrier markings to multi-language paper booklets, electronic instructions for use (eIFU portals), website technical downloads, graphical user interface (GUI) strings, and implant cards—cites the exact same master revision code. Each packaging level must pass the mandatory pre-release accuracy examination required under 21 CFR 820.45 before any product is staged or released.

flowchart TD
    A["Approved Master Labeling Specification<br/>(Medical Device File / DHF)"] --> B{"Gate 1: Units, Numbers & Dates"}
    B -- "Unit conversion unverified<br/>or non-ISO date syntax" --> FAIL1["FAIL: Reject Artwork<br/>Re-align with Master Spec"]
    B -- "Locked SI units preserved<br/>YYYY-MM-DD verified" --> C{"Gate 2: Symbols & Glossaries"}
    C -- "Outdated symbol edition,<br/>divergent glossary, or improper 5.7.8" --> FAIL2["FAIL: Reject Artwork<br/>Re-verify Recognized Standard"]
    C -- "Harmonised/Recognized graphics<br/>and full glossary fields verified" --> D{"Gate 3: Version Identity & 820.45 Exam"}
    D -- "Version mismatch across media<br/>or lagging eIFU/website file" --> FAIL3["FAIL: Halt Release<br/>Reconcile Master Revision"]
    D -- "Identical revision code across all media<br/>and 820.45 accuracy exam passed" --> PASS["Final QA/RA Release Sign-Off<br/>Commercial Artwork Issuance"]
    FAIL1 --> A
    FAIL2 --> A
    FAIL3 --> A

To establish an enforceable standard operating procedure (SOP), QA/RA teams must delineate between translatable narrative prose and locked regulatory identifiers that must remain invariant across all languages:

What the Law Is Actually Asking You to Keep Aligned

Regulatory compliance across major international markets requires aligning distinct statutory baselines. While both the European Union and the United States demand rigorous labeling controls, they enforce different mechanisms regarding language requirements, standardized symbols, and pre-release inspection.

In the European Union, Regulation (EU) 2017/745 (MDR) Article 10(11) establishes that manufacturers must ensure that devices are accompanied by the information specified in Annex I Section 23 in an official Union language or languages determined by the Member State in which the device is made available to the user or patient. Furthermore, all particulars provided on the label must be indelible, easily legible, and clearly comprehensible to the intended user. It is a critical legal reality that there is no single harmonised EU language. The European Commission's publication, MDR — Language requirements for manufacturers — Rev. 3 (August 2025), provides a comprehensive overview of national provisions across 27 Member States and EEA countries. However, the Commission's table explicitly caveats that national legislation takes precedence over the summary document. Check the current national instrument, including Member State registration guides such as France and Germany, rather than treating the Commission overview as the legal language list. The table records that some Member States accept English for selected professional-use documents under national conditions. Those exceptions are national and conditional; they must be verified in the current Member State provision before a market is treated as English-acceptable, and they do not cancel GSPR 23.1(h), Article 10(11) comprehensibility, or the duty to keep any translated copy up to date.

General Safety and Performance Requirement (GSPR) 23.1 further mandates that all identification and safety information must appear on the device, packaging, or IFU, and shall, if the manufacturer has a website, be made available and kept up to date on the website. This statutory obligation creates an immediate release dependency: if an updated translated IFU is released in physical print but the manufacturer's website continues to host a prior revision, the manufacturer is in direct violation of GSPR 23.1. Under GSPR 23.1(h), any graphical information supplied must take the form of internationally recognised symbols conforming to harmonised standards or common specifications.

In the United States, the regulatory baseline is governed by Title 21 of the Code of Federal Regulations. Under 21 CFR 801.15, all required label statements must appear prominently in the English language (with a narrow statutory exception under 801.15(c)(1)(i)(B) for articles distributed solely in Puerto Rico or another Territory where the predominant language is other than English). Stand-alone graphical symbols from standard development organizations (SDOs) are permitted on device labels without adjacent English text only when they satisfy 21 CFR 801.15(c)(1)(i): the symbol must be contained in a standard recognized by FDA, used in accordance with that recognition, and fully explained in an accompanying symbols glossary.

On the manufacturing and quality systems side, the FDA Quality Management System Regulation (QMSR, 21 CFR Part 820), effective February 2, 2026, incorporates ISO 13485:2016 by reference via 21 CFR 820.7. Manufacturers must not cite retired 21 CFR 820.120. Under current 21 CFR 820.45 (Device labeling and packaging controls), manufacturers must maintain documented procedures for labeling integrity, inspection, storage, and handling. Specifically, 21 CFR 820.45 requires that:

• Labeling and packaging must be examined for accuracy prior to release or storage, including the correct Unique Device Identifier (UDI) or UPC, expiration date, storage instructions, handling instructions, and additional processing instructions.

• The release of labeling for use in manufacturing operations, and the results of mix-up-prevention inspections against the medical device file, must be formally documented in accordance with ISO 13485:2016 Clause 4.2.5.

The operational reconciliation duty is synthesized in the comparative regulatory alignment matrix below:

Gate 1: Units of Measurement, Numbers, and Dates

Gate 1 represents the quantitative firewall of the labeling release process. In medical device engineering, units of measurement, quantitative operating parameters, and numerical thresholds are safety-critical data points. If an unauthorized unit conversion occurs, or if a decimal separator is misinterpreted, the clinical risk profile changes immediately.

The process foundation is established in ISO 20417:2026 (Medical devices — Information to be supplied by the manufacturer). The ISO Online Browsing Platform identifies Clause 5 as the information that needs to be established to support creating accompanying information, including units of measurement, graphical information, language and country identifiers, and dates. Clause 5.1 is units of measurement and Clause 5.4 is dates; ISO 80000-1 is listed among references. This article does not reproduce paid ISO 20417 or ISO 80000-1 clause wording and does not invent a mandatory decimal marker. In the European Union, Council Directive 80/181/EEC establishes the International System of Units (SI) as the legal units of measurement for economic, public health, public safety, and administrative purposes. Directive 2009/3/EC removed the sunset on supplementary non-SI indications, so a documented supplementary unit beside the SI legal unit can remain permitted; SI remains the legal baseline.

On United States packaging, over-the-counter (OTC) medical device net quantity declarations are governed by 21 CFR 801.62(l). This OTC net-quantity rule permits only the abbreviations listed in 801.62(l), including mg, ml, mm, kg, l, and mcg (periods and plural forms optional; the closed list also includes other quantity abbreviations such as g and cc). It does not govern every professional-use IFU numeric field. Translators and desktop publishing (DTP) operators must never convert an established SI unit symbol into a spelled-out local word on the primary device label when the approved master specifies the symbol.

A frequent failure mode during translation cycles is the unintentional alteration of decimal markers and thousand separators. In standard American English mathematical notation, 1.5 indicates one and a half, with the period acting as the decimal marker. In European languages (such as German, French, and Spanish), 1,5 uses a comma as the decimal marker. Automated desktop-publishing scripts often convert periods to commas in numerical data tables, or invert thousand-separator spaces and commas. Those transformations are numerical modifications, not language variations. They must be validated against the approved engineering drawing and labeling specification in the medical device file.

Gate 2: Symbols, Glossaries, and Standard Editions

Gate 2 governs graphical communication. The core objective of medical device symbols is to convey critical safety, storage, and operational instructions without relying on translated text. As highlighted in the introduction to ISO 15223-1:2021, standardized symbols exist to simplify labeling and eliminate the need for repetitive linguistic translations across international markets. However, the legal right to substitute text with a symbol depends strictly on adhering to recognized standard editions and maintaining compliant symbols glossaries.

Manufacturers must navigate a significant standards transition between 2026 and 2031. On June 17, 2026, the European Commission published Commission Implementing Decision (EU) 2026/1231 of 11 June 2026, which amended the MDR harmonised standards list by adding entry 12a: EN ISO 15223-1:2021 together with EN ISO 15223-1:2021/A1:2025. Recital (4) of Decision (EU) 2026/1231 notes that Amendment A1:2025 introduces a revised defined term for the authorized representative and modifies the visual symbol so that it is no longer country- or region-specific. As detailed in the MDCG 2021-5 Rev. 1 Appendix, this formalizes the transition from the legacy EC REP symbol to the updated EU REP symbol. The unamended EN ISO 15223-1:2021 citation will be withdrawn on June 15, 2031. During this coexistence window, both symbols remain acceptable under EU MDR. MDCG 2021-5 Rev.1 Appendix states that, within a staggered implementation, it is acceptable to use one or both symbols on different levels of packaging, as well as relabelling or over-labelling solutions, provided the information on the authorised representative remains clear and intelligible. Updating glossary text to A1:2025 while leaving 2021-unamended EC REP artwork on a packaging level is a version mismatch between the legend and the mark, not a completed symbol update. The Decision withdraws the unamended EN ISO 15223-1:2021 reference from 15 June 2031 (Annex point (5)); MDCG describes the 60-month coexistence as running until 17 June 2031. Use the Decision date for the legal withdrawal of entry No 12.

In the United States, FDA recognizes standard editions through its Recognized Consensus Standards database. Under FDA Rec# 5-148 (date of entry 22 December 2025), FDA granted complete recognition to ISO 15223-1:2021 including AMD1:2025. Declarations of conformity (DoC) to the prior recognition (Rec# 5-134) will be accepted only until December 17, 2028. Similarly, FDA recognized the second edition of ISO 20417 (ISO 20417:2026) under FDA Rec# 5-149 on May 25, 2026, with prior edition declarations (Rec# 5-135) accepted until July 1, 2029. Regulatory teams must recognize that FDA consensus recognition does not equal EU legal harmonisation: while ISO 20417:2026 is FDA-recognized, it has not been published in the Official Journal of the European Union as an MDR harmonised standard conferring presumption of conformity.

A critical symbol verification checkpoint in Gate 2 involves ISO 15223-1 Clause 5.7.8 (ISO 7000-3728: Translation). Public manufacturer glossaries quoting ISO 15223-1 5.7.8 give that meaning. ISO 20417:2026 lists Clause 7.4 Translation in its contents; paid clause text is not reproduced here. Industry practice consistent with that clause structure, and with MDR Article 16(3)'s duty to indicate the translation activity and the operator's identity, is to apply 5.7.8 when an entity other than the manufacturer—such as an importer or distributor—translates. Article 16(3) requires the operator to indicate the activity carried out together with its name, registered trade name or registered trade mark, registered place of business, and the address at which it can be contacted. Do not place Symbol 5.7.8 on manufacturer-controlled language packs, because the symbol's published meaning is that original manufacturer information has been translated by another entity.

Gate 3: Released Version Identity Across Media and Packaging

Gate 3 enforces total version identity across the entire medical device information architecture. A common organizational failure occurs when translation files are approved in isolation by local marketing or commercial subsidiaries, resulting in different revisions appearing across packaging components.

The international benchmark for document governance is established in IMDRF/GRRP WG/N52 FINAL:2024 (Edition 2), Principles of Labeling for Medical Devices and IVD Medical Devices. Section 5.1.2 states that labeling should be subject to document (version) control principles. Section 5.1.3 states that, depending on the RA having jurisdiction, labeling may be provided in one or more languages, identified by the plain-text language name or a language code (ISO 639 is referenced). Section 9.3 states that separate professional and lay information, such as a simplified job aid, should agree with the instructions for use and should state clearly the version it relates to.

Under US law, version control is enforced during finished device release. As incorporated into 21 CFR 820.45 under the QMSR, the manufacturer must conduct a thorough accuracy examination prior to releasing labeling. This examination must verify the accuracy of:

1. The Unique Device Identifier (UDI) or Universal Product Code (UPC), ensuring the correct UDI or UPC matches the medical device file and label artwork.

2. The assigned expiration date, verifying that stability study evidence supports the stated shelf life across all translated packaging.

3. Storage and handling instructions, confirming that temperature, humidity, and light restrictions match the approved design specifications.

4. Additional processing and sterilization instructions, ensuring that validated cleaning, disinfection, or autoclave parameters have not been mistranslated.

For in vitro diagnostic (IVD) devices, an additional statutory rule applies: under 21 CFR 809.10(b)(15), the labeling must explicitly state the date of issuance of the last revision of the labeling, identified as such. A multilingual IVD kit whose English insert indicates revision date 2026-03-01 while its French or German insert displays an earlier date (or omits the revision date entirely) represents a direct violation of 21 CFR 809.10(b)(15) and an actionable failure of QMS change control under ISO 13485:2016 document control and medical device file.

To avoid version fragmentation across physical and electronic surfaces, QA teams must execute the cross-media version reconciliation matrix prior to batch release:

Manufacturer-Controlled Packs vs. Article 16 Distributor Translations

A fundamental regulatory fork in global medical device distribution separates translations controlled directly by the legal manufacturer from translations executed by downstream economic operators under EU MDR Article 16.

In a Manufacturer-Controlled Translation, the legal manufacturer oversees the entire development and verification cycle within its certified QMS (ISO 13485:2016 and 21 CFR Part 820). The translated language packs are formal engineering deliverables managed under design controls (ISO 13485 Clause 7.3). They are subject to risk-management review, documented change orders, and pre-release inspection under 21 CFR 820.45. The manufacturer assumes complete legal responsibility for accuracy, post-market surveillance, and regulatory reporting.

Conversely, under EU MDR Article 16(2)(a), an importer or distributor that translates the information supplied by the manufacturer under Annex I Section 23 (in order to make the device available in a specific Member State) does not assume the full obligations of a manufacturer under Article 16(1)(c), provided the activity is strictly limited to translation and repackaging. However, the economic operator must satisfy rigorous statutory requirements under Article 16(3) and 16(4):

• The distributor or importer must have in place a quality management system with procedures that ensure the translation of information is accurate and up-to-date, that the original condition of the device is preserved, and that they are informed of the manufacturer's corrective actions (Article 16(3)).

• In accordance with MDCG 2021-26 (Question 13), the translated IFU should always be an exact translation of the original version provided by the manufacturer. If the manufacturer updates the master IFU from Revision C to Revision D, the distributor cannot continue circulating translated Revision C. Doing so violates Article 16(3).

• Under Article 16(4), the distributor must notify both the legal manufacturer and the national competent authority at least 28 days prior to making the translated device available, provide a sample or mock-up of the relabelled or repackaged device including any translated label and IFU upon request, and submit to the competent authority a notified-body certificate attesting that the operator's QMS complies with Article 16(3).

• Indicate the translation activity and the translating entity's identity as required by Article 16(3). Where ISO 15223-1 5.7.8 is used for that activity, include the operator's name and address; do not treat 5.7.8 as a substitute for the Article 16(3) identity particulars.

flowchart LR
    M["Legal Manufacturer Master Release"] --> FORK{"Translation Governance Fork"}
    FORK -- "Internal Manufacturer Process" --> MFG["Manufacturer-Controlled Language Pack"] 
    MFG --> M1["Design Controls & ISO 13485 QMS"]
    M1 --> M2["21 CFR 820.45 Accuracy Exam"]
    M2 --> M3["Do not apply Symbol 5.7.8"]
    M3 --> M4["Ship in Manufacturer Master Packaging"]
    FORK -- "Third-Party Importer / Distributor" --> DIST["Article 16 Economic Operator"]
    DIST --> D1["MDCG 2021-26 Exact Translation of Rev n"]
    D1 --> D2["Article 16(3) QMS; 16(4) NB certificate"]
    D2 --> D3["28-Day Advance Notice & Mock-Up"]
    D3 --> D4["Indicate activity and operator identity"]
    D4 --> D5["Market Distribution in Target Member State"]

US Bilingual Completeness and the 510(k) Change Boundary

When medical device manufacturers prepare packaging for the United States market, marketing and commercial teams frequently propose adding Spanish, French, or other foreign-language text to cater to diverse patient demographics or enable cross-border distribution with Canada or Latin America. This practice triggers a strict statutory trap under 21 CFR 801.15.

Under 21 CFR 801.15(c)(2), if a device label contains any representation in a foreign language, all words, statements, and other information required by or under the Federal Food, Drug, and Cosmetic Act must appear on the label in that foreign language. Furthermore, under 21 CFR 801.15(c)(3), if the labeling (including the package insert, outer carton, or user manual) contains any foreign-language representation, all required information must appear on the labeling in that foreign language. A manufacturer cannot selectively translate marketing copy, product highlights, or storage headers while leaving contraindications, boxed warnings, or symbols glossary statements in English only. A partial foreign-language translation constitutes statutory misbranding under FD&C Act Section 502(c). Separate Arabic-script and halal-marking rules are a different labeling job; see the MENA Arabic labeling guide.

From a regulatory change control perspective, adding a foreign language to US labeling is governed by FDA's guidance, Deciding When to Submit a 510(k) for a Change to an Existing Device (October 2017). Example 6 of the guidance addresses adding a foreign-language translation of the directions for use. The guidance establishes that although adding a translation could affect directions for use (flowchart question A4), the change can be handled as Documentation only (rather than requiring a new 510(k) submission), provided that a risk-based assessment confirms the translation does not alter the meaning of the instructions.

Similarly, when translating professional labeling into lay language for home-use devices, manufacturers must adhere to FDA's Guidance on Medical Device Patient Labeling. The translation must never alter the clinical intent of warnings, must not introduce unsubstantiated performance claims, and must remain completely consistent with the cleared professional labeling. In the European Union, MDR Article 7 establishes an identical legal boundary, prohibiting any labeling, IFU, or promotional statement that misleads users or patients by ascribing functions the device does not possess.

What Not to Close as Translation-Complete: Fail-Closed Audit Triggers

To protect patient safety and maintain inspection readiness, medical device quality organizations must operate on a fail-closed basis: artwork release sign-off must be refused if any single verification check fails across the three gates. The following real-world audit triggers mandate immediate rejection of artwork proofs and translation files:

By embedding these three gates into corporate standard operating procedures and establishing automated inspection controls, medical device manufacturers ensure that global translations preserve scientific accuracy, satisfy strict statutory requirements, and protect clinical users across every international market.